UOC
NVAX icon

UBS O'Connor’s Novavax NVAX Stock Holding History

UBS O'Connor’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-39,100
Closed -$4.04M – 482
2016
Q1 		$4.04M Buy
+39,100
New +$4.19M 0.04% 275
2015
Q1 		– Sell
-1,170
Closed -$139K – 839
2014
Q4 		$139K Buy
+1,170
New +$122K ﹤0.01% 609
2013
Q4 		– Sell
-16,581
Closed -$1.05M – 471
2013
Q3 		$1.05M Buy
+16,581
New +$934K 0.02% 293

Other funds holding NVAX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS O'Connor's NVAX Position: Q2 2016 in Review

UBS O'Connor sold out of Novavax (NVAX) in Q2 2016, closing a stake of 39,100 shares — an estimated $4.04M sold.

UBS O'Connor first reported a position in NVAX in Q3 2013 and held it in 3 quarters. The position peaked at $4.04M in Q1 2016. 187 funds tracked by Wall St. Rank hold NVAX as of Q2 2016.

  • UBS O'Connor reported no remaining Novavax position as of Q2 2016 after selling out during the quarter.
  • UBS O'Connor sold 39,100 Novavax shares in Q2 2016, an estimated $4.04M.
  • UBS O'Connor first reported a position in Novavax in Q3 2013 and held it in 3 quarters.
  • UBS O'Connor's Novavax position peaked at $4.04M in Q1 2016.
  • 187 funds tracked by Wall St. Rank held Novavax as of Q2 2016.

Based on UBS O'Connor's 13F filing for Q2 2016, filed 12 Aug 2016.